CL2008000987A1 - Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina; procedimiento de preparacion, util para tratar enfermedades mediadas por rage, tales como alzheimer, cancer, inflamacion aguda y cronica, - Google Patents

Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina; procedimiento de preparacion, util para tratar enfermedades mediadas por rage, tales como alzheimer, cancer, inflamacion aguda y cronica,

Info

Publication number
CL2008000987A1
CL2008000987A1 CL200800987A CL2008000987A CL2008000987A1 CL 2008000987 A1 CL2008000987 A1 CL 2008000987A1 CL 200800987 A CL200800987 A CL 200800987A CL 2008000987 A CL2008000987 A CL 2008000987A CL 2008000987 A1 CL2008000987 A1 CL 2008000987A1
Authority
CL
Chile
Prior art keywords
penoxi
dietil
propil
butil
amina
Prior art date
Application number
CL200800987A
Other languages
English (en)
Spanish (es)
Inventor
Hari Anitha
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of CL2008000987A1 publication Critical patent/CL2008000987A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
CL200800987A 2007-04-05 2008-04-04 Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina; procedimiento de preparacion, util para tratar enfermedades mediadas por rage, tales como alzheimer, cancer, inflamacion aguda y cronica, CL2008000987A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92196407P 2007-04-05 2007-04-05
US92578607P 2007-04-23 2007-04-23

Publications (1)

Publication Number Publication Date
CL2008000987A1 true CL2008000987A1 (es) 2008-08-08

Family

ID=39469930

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800987A CL2008000987A1 (es) 2007-04-05 2008-04-04 Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina; procedimiento de preparacion, util para tratar enfermedades mediadas por rage, tales como alzheimer, cancer, inflamacion aguda y cronica,

Country Status (11)

Country Link
US (2) US7884219B2 (enExample)
EP (1) EP2144883A1 (enExample)
JP (1) JP2010523559A (enExample)
AR (1) AR065896A1 (enExample)
CA (1) CA2681864A1 (enExample)
CL (1) CL2008000987A1 (enExample)
PA (1) PA8775601A1 (enExample)
PE (1) PE20090808A1 (enExample)
TW (1) TW200900384A (enExample)
UY (1) UY31004A1 (enExample)
WO (1) WO2008123914A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523559A (ja) * 2007-04-05 2010-07-15 トランス テック ファーマ，インコーポレイテッド ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
US9717710B2 (en) * 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
NZ739521A (en) * 2012-10-05 2019-06-28 Vtv Therapeutics Llc Pharmaceutical compositions
CN103726005A (zh) * 2012-10-16 2014-04-16 深圳富泰宏精密工业有限公司 珐琅涂层的制造方法及其制品
WO2019190822A1 (en) * 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2020076668A1 (en) * 2018-10-10 2020-04-16 Vtv Therapeutics Llc Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
WO2020086388A1 (en) 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
US11648235B1 (en) 2022-12-30 2023-05-16 Cantex Pharmaceuticals, Inc. Treatment of glioblastoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075921A2 (en) * 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
WO2005000295A1 (en) 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
JP2010523559A (ja) * 2007-04-05 2010-07-15 トランス テック ファーマ，インコーポレイテッド ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態

Also Published As

Publication number Publication date
AR065896A1 (es) 2009-07-08
US20110166361A1 (en) 2011-07-07
JP2010523559A (ja) 2010-07-15
UY31004A1 (es) 2008-11-28
PE20090808A1 (es) 2009-06-27
US8372988B2 (en) 2013-02-12
EP2144883A1 (en) 2010-01-20
PA8775601A1 (es) 2009-04-23
US7884219B2 (en) 2011-02-08
TW200900384A (en) 2009-01-01
CA2681864A1 (en) 2008-10-16
WO2008123914A1 (en) 2008-10-16
US20080249316A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
CL2008000987A1 (es) Formas cristalinas de [3-(4-{2-butil-1-[4-(4-cloro-fenoxi)-fenil]1h-imidazol-4-il}-fenoxi)-propil]-dietil-amina; procedimiento de preparacion, util para tratar enfermedades mediadas por rage, tales como alzheimer, cancer, inflamacion aguda y cronica,
EP2768514A4 (en) LOCALIZED MODULATION OF TISSUES AND CELLS TO IMPROVE THERAPEUTIC EFFECTS INCLUDING RENAL RECURRING
CL2014000296A1 (es) Compuestos derivados de sulfoxidos de 2-(piperidin-1-il)-dihidrotieno[3,2-d]pirimidina; metodo de preparacion; compuestos intermediarios; y uso para tratar enfermedades inflamatorias o alergicas tales como epoc y asma.
WO2013151668A3 (en) Modified polynucleotides for the production of secreted proteins
HK1206612A1 (en) Modified polynucleotides for the production of secreted proteins
EP2350110A4 (en) NEW STEVIOLGLYKOSIDE
EP3190186C0 (en) EXPRESSION OF MIRNAS IN PLACENTAL TISSUE
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
DK2510150T3 (da) Hidtil ukendt fremgangsmåde til behandling af lignocelluloseholdigt materiale
BR112014012539A2 (pt) moléculas de ligação específicas para her3 e usos dessas
ITTO20110627A1 (it) Composizione farmaceutica di combinazione e metodi per trattare diabete e patologie metaboliche
BR112013017669A2 (pt) di-hidrofuranos fundidos como moduladores de gpr119 para o tratamento de diabetes, obesidade e doenças relacionadas
BRPI0914614A2 (pt) 2-arilaminoquinazolinas para tratar doenças proliferativas
IL228090A0 (en) Compositions and methods for personal tumor profiling treatment
DK2461812T3 (da) Præparat til behandling af cystisk fibrose
BRPI0919327A2 (pt) compostos ligados a enxofre para tratar doenças e distúrbios oftálmicos
IL228771A0 (en) Glycoside derivatives and their uses for the treatment of diabetes
BRPI1005380A2 (pt) colírio com difluprednato para tratar edema macular, e uso de difluprednato para produzir o dito colírio
BR302013001867S1 (pt) Configuração aplicada em aparelho para reprodução de sons
CL2007003194A1 (es) Formas cristalinas del hemi fumarato de alisquireno; procedimiento de preparacion; composicion farmaceutica que comprende a dichas formas cristalinas; y su uso para tratar enfermedades que se modulan con bloqueo del receptor at1, tales como regulacio
BR112013016365A2 (pt) composição de lipossoma e processo para produção do mesmo
BR112013025392A2 (pt) composição, uso de perlita e de pelo menos um polímero vinílico e processo de tratamento cosmético
EP2247297A4 (en) THERAPEUTIC TREATMENT OF LUNG DISEASES
BR112012006437A2 (pt) composições e métodos para tratamento do diabetes e outros distúrbios
BRPI0923377A2 (pt) Derivados de 1-amino-alquilciclohexano para o tratamento de doenças mediadas por mastócitos